Founded in 2013 and based in St. Louis, MO, Acera delivers new technology and is revolutionizing patient care.
In 2009, while an MD / Ph.D. student at Washington University, Matthew MacEwan worked with bioengineering graduate students investigating methods to create novel polymer biomaterials. Matthew was intrigued by the structure and its unique properties and focused his research on the potential use of these fibers in the medical field.
The turning point came in the summer of 2011 when Matthew was first introduced to Agnès Rey-Giraud, a retired Senior Executive and sought after industry leader. Together, they built the business case for a potential product and pursued the path to clinical validation, FDA clearance, and commercialization.
Following successful product tests, the business progressed to the development of Cerafix, a fully synthetic dural repair matrix whose scale and architecture resembles native tissue. In 2016, the device received clearance to be marketed and distributed in the U.S. It was soon followed by Restrata, offering a fully resorbable, engineered electrospun fiber matrix for soft-tissue repair. All Acera products are based on the groundbreaking electrospun fiber matrix technology in which Matthew and Agnès saw such potential and worked to bring to market.
We started Acera, built a team, and grew an idea from the laboratory into the first commercially available electrospun dura substitute in the U.S.
- Matthew MacEwan, PhD, Chief Scientific Officer
Innovative technological solutions backed by proven results and a foundational passion for improving lives drives Acera to continue advancing the field of soft-tissue repair. The proven healing power of the electrospun fiber matrix technology pioneered by Acera is now available in surgical matrices, providing relief to patients who suffer from surgical wounds, trauma, burns, and chronic wounds, among other indications.